Photo: a medical worker in India took a group photo with a billboard after receiving the new crown vaccine on the 25th. /Agence France Presse
[Ta Kung Pao] according to a comprehensive report by Bloomberg and voice of Germany, many countries are suffering from a shortage of vaccines, while in India, on the contrary, although there are a large number of vaccines, few people are willing to inject them. Qualified groups, including doctors and nurses, are suspicious of vaccines, especially covaxin, a local vaccine whose effectiveness is unknown. The recently publicized “vaccine diplomacy” of the Indian government also gave away the covishield vaccine, which was jointly developed by British Pharmaceutical Company AstraZeneca and Oxford University and produced by the Serum Institute of India (SII), rather than the “domestic product”;.
At present, two new vaccines for the public in India are covishield, an Indian version of Oxford vaccine, and covaxin, a native covaxin vaccine developed by Bharat biotechnology company in India. The country launched the new crown vaccination program on January 16, hoping to vaccinate 300 million people by July. The first batch of vaccinators are 10 million medical and nursing personnel, the second batch is 20 million front-line personnel, and then there are 270 million high-risk groups.
By the 26th, only 2 million people in India had completed the vaccination, but a large number of people had no confidence in the domestic vaccine. For example, in the southern state of Tamil Nadu, 56% of the people who made an appointment for the covishield vaccine on the 19th arrived on schedule, but only 23.5% of the people who made an appointment for the covaxin vaccine showed up. It is reported that the covaxin vaccine only & lt; completed the early trial & gt;, and the effectiveness data has not been published so far.
India has also publicized the “vaccine diplomacy” of modi government recently. From January 20 to 23, India has provided Myanmar and other neighboring countries with more than 4.9 million doses of new vaccine free of charge. Besides Myanmar, the covishield vaccine produced by the Serum Institute of India has also arrived in Maldives, Bhutan, Bangladesh and Nepal, Reuters reported. In addition, Sri Lanka is expected to receive 500000 doses of Indian vaccine on January 25, and Afghanistan is also on the waiting list.
Rajiv Bhatia, India’s former Consul General in Toronto, said India would demonstrate the effectiveness of the “neighborhood first” policy with actions. “It’s a demonstration of our strength in science and pharmacy, and it’s a glorious moment for us,” he said. &”But he didn’t explain why he didn’t give covaxin, which was independently developed by India, to such a glorious moment.